dc.contributor.authorPal, Arumay
dc.contributor.authorNeo, Kurt
dc.contributor.authorRajamani, Lakshminarayanan
dc.contributor.authorFerrer, Fernando Jose
dc.contributor.authorLane, David P.
dc.contributor.authorVerma, Chandra Shekhar
dc.contributor.authorMortellaro, Alessandra
dc.date.accessioned2019-05-17T08:55:22Z
dc.date.available2019-05-17T08:55:22Z
dc.date.issued2019
dc.identifier.citationPal, A., Neo, K., Rajamani, L., Ferrer, F. J., Lane, D. P., Verma, C. S., & Mortellaro, A. (2019). Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides. Scientific Reports, 9, 4913-. doi:10.1038/s41598-019-41211-3en_US
dc.identifier.urihttp://hdl.handle.net/10220/48277
dc.description.abstractInterleukin-1β (IL-1β) is a major cytokine that initiates and enhances inflammatory responses. Excessive IL-1β production is a characteristic of most chronic inflammatory diseases, including atherosclerosis, type 2 diabetes, and obesity, which affect a large proportion of the global population. The production of bioactive IL-1β is mediated by a caspase-1-activating complex known as an ‘inflammasome’. The NLRP3 inflammasome has been associated with several human inflammatory and autoimmune diseases and represents a potential therapeutic target for disrupting IL-1β production. We used molecular modeling guided by molecular dynamics simulations to design α-helical stapled peptides targeting the pyrin domain of the adaptor protein ASC to interrupt the development of its filament, which is crucial for NLRP3 inflammasome formation. The peptides were effectively internalized by human monocytic cells and efficiently suppressed the release of the inflammasome-regulated cytokines IL-1β and IL-18, following exogenous activation of the NLRP3 inflammasome. The peptides reduced ASC speck formation and caspase-1 processing thereby suppressing pro-IL-1β processing and release of active IL-1β. This is the first demonstration of the successful use of stapled peptides designed to target the adaptor protein ASC, and can be extended to other inflammatory pathways to disrupt excessive IL-1β production.en_US
dc.description.sponsorshipASTAR (Agency for Sci., Tech. and Research, S’pore)en_US
dc.format.extent15 p.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesScientific Reportsen_US
dc.rights© 2019 The Author(s) (Nature Publishing Group). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.en_US
dc.subjectInflammasomeen_US
dc.subjectMolecular Modellingen_US
dc.subjectDRNTU::Science::Biological sciencesen_US
dc.titleInhibition of NLRP3 inflammasome activation by cell-permeable stapled peptidesen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.identifier.doihttp://dx.doi.org/10.1038/s41598-019-41211-3
dc.description.versionPublished versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record